AN2 Therapeutics, Inc.
ANTX
$5.73
-$0.25-4.18%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 2.95% | 23.81% | 31.46% | 44.01% | 42.19% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -27.38% | -7.79% | 2.31% | 7.00% | 10.86% |
| Change in Net Operating Assets | 138.43% | 27.04% | 105.48% | 80.67% | -189.07% |
| Cash from Operations | 13.58% | 26.02% | 39.43% | 51.07% | 41.65% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -33.32% | -26.90% | -48.14% | -76.96% | 239.26% |
| Cash from Investing | -33.32% | -26.90% | -48.14% | -76.96% | 239.26% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 44,347.73% | 42,373.86% | -69.62% | -69.62% | -99.87% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 44,065.91% | 42,373.86% | -69.62% | 121.57% | -99.87% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 405.28% | 811.60% | -124.72% | -1,845.61% | 39.12% |